Home Cart Sign in  
Chemical Structure| 89226-75-5 Chemical Structure| 89226-75-5

Structure of Manidipine Dihydrochlorid
CAS No.: 89226-75-5

Chemical Structure| 89226-75-5

Manidipine Dihydrochlorid

CAS No.: 89226-75-5

Manidipine 2HCl is a L/T-typecalcium channel blocker for Ca2+ current with IC50 of 2.6 nM.

Synonyms: CV-4093; Manidipine 2HCl; Manidipine dihydrochloride

4.5 *For Research Use Only !

Cat. No.: A108830 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
10mg łÇǶÊÊ Inquiry Inquiry
50mg łÇͶÊÊ Inquiry Inquiry
100mg łÇď¶ÊÊ Inquiry Inquiry
250mg łË§¶ÊÊ Inquiry Inquiry
1g łÍÿ¶ÊÊ Inquiry Inquiry
5g łÇòǶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 10mg

    łÇǶÊÊ

  • 50mg

    łÇͶÊÊ

  • 100mg

    łÇď¶ÊÊ

  • 250mg

    łË§¶ÊÊ

  • 1g

    łÍÿ¶ÊÊ

  • 5g

    łÇòǶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Manidipine Dihydrochlorid

CAS No. :89226-75-5
Formula : C35H40Cl2N4O6
M.W : 683.62
SMILES Code : O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5.[H]Cl.[H]Cl
Synonyms :
CV-4093; Manidipine 2HCl; Manidipine dihydrochloride
MDL No. :MFCD00896434

Safety of Manidipine Dihydrochlorid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Calcium Channel

    Calcium channel, IC50:2.6 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 10 μM 24 hours Evaluate the inhibitory effect of Manidipine on HTNV replication PMC9465303
Huh-7 cells 20 μg/mL 48 hours Evaluate the effect of Manidipine on SFTSV replication, results showed Manidipine significantly reduced SFTSV production PMC10062178
SW13 cells 20 μg/mL 48 hours Evaluate the effect of Manidipine on SFTSV replication, results showed Manidipine significantly reduced SFTSV N-positive cells PMC10062178
SKOV3-SP cells 10 µM 8 days Reduced sphere viability PMC7177693
A2780-SP cells 10 µM 8 days Reduced sphere formation and viability, induced apoptosis PMC7177693
Bacillus subtilis L-form 0.53 μM (EC50) Manidipine significantly inhibited the growth of L-form bacteria while having no significant effect on walled cells. PMC10110866

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c-nu/nu mice A2780-SP cells xenograft model Intraperitoneal injection 1mpk Every 4 days for 31 days Inhibited tumor growth, reduced stem cell marker expression PMC7177693
IFNAR−/− mice Lethal SFTSV infection model Intraperitoneal injection 10 mg/kg Twice daily for 2 days Evaluate the effect of Manidipine on survival rate and viral load in SFTSV-infected mice, results showed Manidipine significantly increased survival rate and reduced viral load in the spleen PMC10062178

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00157586 Type 2 Diabetes Phase 3 Completed - Italy ... More >> ASL of Ponte San Pietro - Diabetologic Unit Ponte San Pietro, Bergamo, Italy, 24036 Clinical Research Center for Rare Diseases Ranica, Bergamo, Italy, 24020 Hospital of Romano di Lombardia - Diabetologic Unit Romano di Lombardia, Bergamo, Italy, 24058 Hospital " Bolognini " - Medicine Unit Seriate, Bergamo, Italy, 24068 Hospital " Treviglio Caravaggio" - Diabetologic Unit Treviglio, Bergamo, Italy, 24128 Humanitas Institute - Endocrinology and Diabetologic Unit Rozzano, Milano, Italy, 20089 Hospital "Ospedali Riuniti di Bergamo" - Diabetologic Unit Bergamo, Italy, 24128 Slovenia Department of Endocrinolgy, Diabetes and Metabolic Disease - University Medical Center Lubiana, Slovenia Less <<
NCT03106597 Hypertension Phase 4 Recruiting December 10, 2018 Korea, Republic of ... More >> Yonsei University Severance Hospital Recruiting Seoul, Korea, Republic of, 03722 Contact: Sang Hak Lee, MD, PhD    82-10-5472-6911    shl1106@yuhs.ac    Sub-Investigator: Sang Hak Lee, MD, PhD          Korea University Guro Hospital Recruiting Seoul, Korea, Republic of, 08308 Contact: Seung-hoe Song, MBE    82-2-2626-1635    ssessong@korea.ac.kr    Contact: Da-in Lee    82-2-2626-2279    0124dain@gmail.com    Yonsei University Wonju Hospital Recruiting Wonju, Korea, Republic of, 26426 Contact: Jang Young Kim, PhD          Contact    82-10-5360-0463    kimjy@yonsei.ac.kr    Sub-Investigator: Jang Young Kim, PhD Less <<
NCT00741585 Essential Hypertension ... More >> Cardiovascular Disease Stroke Chronic Kidney Disease Less << Phase 4 Completed - Spain ... More >> CS Friol Friol, Lugo, Spain, 27220 CS Baiona Baiona, Pontevedra, Spain, 36300 CS Bueu Bueu, Pontevedra, Spain, 36930 CS A Estrada La Estrada, Pontevedra, Spain, 26680 CS A Guarda La Guardia, Pontevedra, Spain, 36780 CS Valmiñor Nigran, Pontevedra, Spain, 36250 CS Panxón Nigrán, Pontevedra, Spain, 36340 CS Tomiño Tomiño, Pontevedra, Spain, 36200 Bioengineering & Chronobilogy Labs., University of Vigo Vigo, Pontevedra, Spain, 36200 Hospital do Meixoeiro Vigo, Pontevedra, Spain, 36200 CS Calle Cuba Vigo, Pontevedra, Spain, 36202 CS A Doblada Vigo, Pontevedra, Spain, 36205 CS Coia Vigo, Pontevedra, Spain, 36209 CS Sardoma Vigo, Pontevedra, Spain, 36214 CS Teis Vigo, Pontevedra, Spain, 36216 CS Vilaboa Vilaboa, Pontevedra, Spain, 36141 CS San Roque Vilagarcía De Arousa, Pontevedra, Spain, 36600 CS Fingoi Lugo, Spain, 27002 Complexo Hospitalario Universitario de Ourense Orense, Spain, 32005 CS Lerez Pontevedra, Spain, 36156 Less <<
NCT00627952 Hypertension Phase 3 Completed - Germany ... More >> Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nurnberg Erlangen, Bavaria, Germany, 91054 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.46mL

0.29mL

0.15mL

7.31mL

1.46mL

0.73mL

14.63mL

2.93mL

1.46mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories